Navigation Links
New Drug Boosts 'Good' Cholesterol in Study Patients
Date:9/13/2011

TUESDAY, Sept. 13 (HealthDay News) -- A treatment currently being studied may prevent progression of atherosclerosis, a condition caused by the build-up of plaque in artery walls that can lead to heart attack, according to new research.

In conducting the study, published in the Sept. 12 issue of The Lancet, researchers followed 130 patients with atherosclerosis who were randomly assigned to be treated with either the experimental heart drug dalcetrapib, or an inactive placebo over the course of two years. In the double-blind study, neither the researchers nor the patients knew who was taking the heart drug and who was taking the placebo.

While statin drugs are commonly used to lower LDL or "bad" cholesterol to reduce the risk of coronary artery disease, dalcetrapib raises HDL or "good" cholesterol in order to reduce the risk, the researchers explained.

To determine the efficacy of dalcetrapib, the researchers used non-invasive imaging technology. Through MRI, the researchers found the patients on dalcetrapib had a 31 percent increase in "good" HDL cholesterol levels. Additional PET/CT scans showed that inflammation levels in the carotid artery of patients were significantly reduced only among those taking dalcetrapib. The carotid arteries are responsible for supplying oxygenated blood to the head and neck.

In a different study, a drug in the same class designed to raise HDL levels was tied to an increase in death linked to vascular inflammation, but the researchers did not find an increase in such inflammation with dalcetrapib.

"This milestone study shows that MRI and PET/CT are highly useful in assessing the safety and efficacy of dalcetrapib, and that this novel therapy may address a significantly unmet need in cardiovascular disease," said lead study author Zahi A. Fayad, a professor of radiology and medicine in the cardiology division at Mount Sinai School of Medicine and the director of its Translational and Molecular Imaging Institute, in a Mt. Sinai news release.

"We are excited about the results obtained in this trial, which could have a great impact on the treatment of patients with cardiovascular disease," said Fayad, who disclosed receiving financial compensation as a scientific advisory board member from the study's sponsor, Hoffmann-La Roche, whose holding company makes dalcetrapib.

Fayad noted imaging technology could be a vital tool for evaluating other treatments for heart disease.

More information

The U.S. National Library of Medicine has more about atherosclerosis.

-- Mary Elizabeth Dallas

SOURCE: Mount Sinai Hospital, news release, Sept. 12, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. TNF Treatment for Rheumatoid Arthritis Boosts Skin Cancer Risk
2. Regular Exercise Boosts the Brain, Too
3. Yoga boosts stress-busting hormone, reduces pain: York U study
4. Stopping Daily Aspirin Boosts Heart Attack Risk: Study
5. Study: Potassium Boosts Heart Health, Salt Harms It
6. Even One Glass of Beer, Wine Boosts Car Crash Risk: Study
7. Mystery ingredient in coffee boosts protection against Alzheimers disease
8. On-the-Job Activity Boosts Americans Exercise Levels
9. Weight Loss in Heavy, Obese Women Boosts Vitamin D Levels
10. Losing more than 15 percent of body weight significantly boosts vitamin D levels in overweight women
11. Tai Chi Prevents Falls, Boosts Mental Health in Seniors: Study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Drug Boosts 'Good' Cholesterol in Study Patients
(Date:7/21/2017)... , ... July 21, 2017 , ... West Dermatology is ... Doan Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large ... of experience in dermatology, skin cancer , and more. She graduated from the ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... concussion rates are on the rise, say researchers presenting their work at the ... Ontario, Canada. , “The combination of evaluating the patterns of change in concussion ...
(Date:7/20/2017)... ... 20, 2017 , ... Acute myeloid leukemia (AML) is a ... without treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem cell ... With such a challenging diagnosis that requires immediate action, patients and caregivers need ...
(Date:7/20/2017)... ... July 20, 2017 , ... For individuals with extended hospital stays or ... used in such facilities are specially designed to accommodate patients with a wide range ... An inventor from Rochester, Ind., has invented the patent-pending PORTABLE ARM REST, a specially ...
(Date:7/20/2017)... ... July 20, 2017 , ... Doctors on Liens, the leading network ... Horine Chiropractic , directed by Dr. Russell Horine, DC to their exclusive list of ... with Dr. Russell Horine serving as the clinic director and his son Dr. Lee ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... CarpalAID is a revolutionary new product that relieves painful carpal tunnel ... syndrome affects more than 8 million people a year. Women suffer ... common methods of treating CTS are painful surgery, the use of ... ... is a clear patch worn on the palm of the hand. ...
(Date:7/11/2017)... Research Corp., also known as ,The Epigenetics Company, announced today the release ... manner using the myDNAge ™ test. Based on Horvath,s Clock, so ... and biostatistics at the David Geffen School of Medicine at UCLA ... DNAge ™ technology is used to analyze DNA methylation patterns of ... ...
(Date:7/11/2017)... Md. , July 11, 2017  The global ... estimated revenues of approximately $394.1 million in 2016.  Although ... trend of solid growth, in particular as a result ... clinical practice, and the recent introduction of a significant ... need for less-invasive testing of tumor biomarkers to guide ...
Breaking Medicine Technology: